1. ¹New England Research Institutes, Watertown, MA, USA
2. ²Case Medical Center/University Hospitals of Cleveland, Cleveland, OH, USA
3. ³Section of Urology, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA

Correspondence: Dr RC Rosen, New England Research Institutes, 9 Galen Street, Watertown, MA 02472, USA. E-mail: rrosen@neriscience.com

Abstract

Erectile dysfunction (ED) and benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) share many epidemiologic and clinical similarities. First-line therapy for both conditions include oral medications ( blockers, phosphodiesterase inhibitors). The impetus to develop and use questionnaires to characterize these two conditions is based on the trend away from invasive diagnostic testing to the use of patient-reported outcomes or validated self-administered questionnaires. The International Prostate Symptom Score, the International Index of Erectile Function, the Male Sexual Health Questionnaire (MSHQ) and the MSHQ short form are similar patient-reported assessment questionnaires used for research or clinical evaluation of BPH/LUTS, ED and ejaculatory dysfunction. These patient-based self-administered questionnaires are likely to assume an ever increasing important role in the future, as oral BPH therapies are considered for the treatment of ED and oral ED therapies are considered for the treatment of BPH/LUTS.